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Background: Antifolates have been effective antimalarial drugs.
Results: Two proteins of P. falciparum facilitate membrane transport of folates but also of pABA, a precursor of folates.
Conclusion: At the concentration that pABA is in the human plasma it would have a higher impact on the parasite’s fitness.
Significance: pABA metabolism could be a valuable target in the effort to further antimalarial chemotherapy.
Tetrahydrofolates are essential cofactors for DNA synthesis
andmethioninemetabolism.Malaria parasites are capable both
of synthesizing tetrahydrofolates and precursors de novo and of
salvaging them from the environment. The biosynthetic route
has been studied in some detail over decades, whereas the
molecular mechanisms that underpin the salvage pathway lag
behind. Here we identify two functional folate transporters
(named PfFT1 and PfFT2) and delineate unexpected substrate
preferences of the folate salvage pathway in Plasmodium falcip-
arum. Both proteins are localized in the plasma membrane and
internal membranes of the parasite intra-erythrocytic stages.
Transport substrates include folic acid, folinic acid, the folate
precursor p-amino benzoic acid (pABA), and the human folate
catabolite pABAGn. Intriguingly, the major circulating plasma
folate, 5-methyltetrahydrofolate, was a poor substrate for trans-
port via PfFT2 and was not transported by PfFT1. Transport of
all folates studied was inhibited by probenecid and methotrex-
ate. Growth rescue inEscherichia coli and antifolate antagonism
experiments in P. falciparum indicate that functional salvage of
5-methyltetrahydrofolate is detectable but trivial. In fact pABA
was the only effective salvage substrate at normal physiological
levels. Because pABA is neither synthesized nor required by the
humanhost, pABAmetabolismmay offer opportunities for che-
motherapeutic intervention.
Tetrahydrofolate (THF) derivatives are essential cofactors
for single carbon transfer reactions in the synthesis of nucleic
acids and methionine (1). Whereas humans rely on the dietary
intake of preformed folates, many pathogenic microorganisms,
includingPlasmodium falciparum, are capable of de novo folate
biosynthesis from the condensation of pteridines, p-amino
benzoic acid (pABA)3 and glutamate. Consequently, antifolate
drugs that target the biosynthesis and processing of folate
cofactors have been effectively used in the treatment of infec-
tious diseases, including P. falciparummalaria (2, 3).
P. falciparum parasites are also able to salvage preformed
folates and related metabolites from the surrounding culture
medium in vitro (4–6). The relationship between the biosyn-
thetic and salvage pathways and their relative importance to
parasite viability and antifolate drug susceptibility is poorly
understood. The consensus view is that both processes are nec-
essary for the parasite to thrive (2, 3, 6–13). Many studies have
demonstrated that the salvage of folates and relatedmetabolites
added to the surroundingmedium reduces the sensitivity of the
parasite to antifolate drugs (5, 6, 14, 15). Presumably the salvage
of folates will bypass steps in the de novo synthesis pathway,
thus antagonizing the activity of these antifolate drugs (3).
Folates are di-anionic at physiological pH (pKa 2.3 and 8.3),
and the efficient passage of these highly polar molecules
through biological membranes generally requires specific
membrane transporters. Indeed, a recent study has demon-
strated that folate uptake by P. falciparum parasites is a specific
energy-dependent, saturable process that can be inhibited by
the classical anion transport inhibitors probenecid and furo-
semide (13). These findings are consistent with the hypothesis
that folate salvage is mediated by specific transporters.
Other studies have shown that probenecid (an inhibitor of
anion membrane transport) markedly increases the sensitivity
of P. falciparum to antifolate drugs both in vitro and in vivo (16,
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17). Themost logical explanation for the increased sensitivity to
antifolates is due to probenecid inhibiting the transport of
folates into the parasite (13, 16). These exciting findings illus-
trate the potential of blocking folate salvage transporters as a
therapeutic strategy and give clues to the molecular basis of
folate transport.
Here we report the identification and characterization of two
folate transporters expressed in Xenopus oocytes and Esche-
richia coli. Confirmation of substrate preference and inhibitor
specificity in cultured parasites supports a role for these plasma
membrane transporters in folate salvage in P. falciparum. An
apparent reliance of P. falciparum on the salvage of the folate
precursor pABA, rather than 5-methyltetrahydrofolate, the
principal circulating folate, offers new possibilities for potential
antimalarial drug development.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents—Radiolabeled compounds [3,5,7,9-3H]
folic acid (10 Ci/mmol), 5-[14C]methyltetrahydrofolate (52
mCi/mmol), and [3,5,7,9-3H(N)]folinic acid (10 Ci/mmol)
were purchased from American Radiolabeled Chemicals (St.
Louis, MO) or Moraveck (Brea, CA). Non-radiolabeled folates
and other chemicals were purchased from Sigma or Schircks
Laboratories (Jona, Switzerland). Restriction endonucleases
were obtained from New England Biolabs (Ipswich, MA). Oli-
gonucleotides and molecular biology reagents were purchased
from Invitrogen.
Parasite Culture and Drug Sensitivity Assays—Parasites of
P. falciparum strains 3D7, HB3, K1, and Dd2 were maintained
in continuous culture using standard methods (18, 19). Para-
sites were grown in folate and pABA free medium (see below)
using O erythrocytes that had been exhaustively washed in
folate and pABA free RPMI 1640. Drug sensitivity assays were
performed as published (18) with parasite growthmonitored by
either [3H]hypoxanthine incorporation or SYBRGreen fluores-
cence (20). Each sensitivity assay was performed in triplicate
with a minimum of four experimental replicates. Folate and
pABA-free culture media were 0.5% AlbumaxII (Invitrogen),
folate and pABA-free RPMI 1640 (custom made by HyClone,
ThermoScientific, UK), and 40 M hypoxanthine, 2 M gluta-
mine, 20 g/ml gentamycin, 0.2% sodium bicarbonate, and 25
mM HEPES (pH 7.4). Sulfadoxine (SDX), dapsone, cycloguanil,
and pyrimethamine (PYR) were dissolved in dimethyl sulfox-
ide. pABA, pABA monoglutamate (pABAG1), pABA digluta-
mate (pABAG2), pteroic acid, dipteroic acid, folic acid (FA),
folic acid diglutamate, folinic acid (FoA), methotrexate (MTX),
and probenecid (PBN) were dissolved in 0.1 N sodium hydrox-
ide. 5-methyltetrahydrofolate (5-MTHF) was dissolved in 0.5 M
potassium phosphate, pH 7, and 1% v/v (128.2 mM) of 2-mer-
captoethanol. Stock solutions were filtered through a 0.2 m
Millipore filter.
SequenceAnalyses—MAL8P1.13 (referred to subsequently as
PfFT1), PF11_0172 (referred to subsequently as PfFT2), and
PF10_0215 open reading frames are reported in PlasmoDB5.3
(21). Others sequences were downloaded from GenBankTM
(22). DNA sequences were analyzed with Staden package soft-
ware. Multiple global alignments were performed with
ClustalW 1.81 (23) and plotted with TeXshade (24). Protein
transmembrane fragments were predicted with HMMTOP 2.0
(25) and plotted with TeXtopo (26).
Constructs Cloning—Gene cDNAs were synthesized with
Thermoscript (Invitrogen) from total RNA of P. falciparum
3D7 and Pfx polymerase (Invitrogen) following the manufac-
turer’s recommendations. Gene-specific primers were as fol-
lows: E63 (5-AGATCTCCACCATGGAAGATGACGAC-
TTC) and E64 (5-GGTAACCTTATTCCAAGGTTATGTC)
for PfFT1 and E79 (5-AGATCTCCACCATGATAGAAAAG-
TCTAA) and E66 (5-GGTAACCTTATCCCTTGGATGT-
TTC) for PfFT2. Bases introduced to make a Kozak consensus
sequence are underlined. Start and stop codons are presented
in bold. Gene products were A-tailed with Taq polymerase and
cloned into pCRII-TOPO vector (Invitrogen). All constructs
were sequence-verified. For Xenopus laevis expression, genes
were subcloned into the pKSMvector derived frompBluescript
(Stratagene) (28). Directional cloning was carried out using the
compatible restriction sites XhoI and SpeI. To make possible a
direct subcloning (HindIII-EcoRI) of the human reduced folate
carrier hRFC1 into pKSM, a carboxyl-terminal truncated ver-
sion (537 amino acids) was used. Shorter, carboxyl-terminal
truncated versions of hRFC1 (530 amino acids) are known to be
functionally expressed in X. laevis oocytes (29).
E. coli Expression and Growth Assays—Strain BN1163 is an
E. coli double gene replacement knock-out lacking both PabA
and AbgT genes, a pABA synthesis enzyme, and the pABAG1
transporter (30, 31), and as such (E. colipabA/abgT) thiswas
used in the present study for the expression of theP. falciparum
PfFT1 and PfFT2 synthetic genes with the codon optimized for
E. coli expression (GenScript Corp., Piscataway, NJ). PfFT1 and
PfFT2 were cloned into the tetracycline-resistant plasmid
pLOI707HE between NotI and SacI sites (replacing the bla
gene) (32). We added a Shine-Dalgarno sequence upstream of
the transporter genes and replaced the first 49 amino acids in
the case of PfFT1 and the first 35 amino acids in the case of
PfFT2with codons 1–37 of the Synechocystis sp. PCC6803 gene
slr0642 as reported in Klaus et al. (31). E. coli BN1163 strain
harboring the pLOI707HE recombinant constructs was cul-
tured in 96-wellmicrotiter plates inminimalmedium (M9 salts,
0.1 mM CaCl2, 0.5 mM MgSO4, 0.4% glucose, 10 g/ml tetracy-
cline, 50 g/ml kanamycin, 20 g/ml chloramphenicol) (33)
with 1 mM isopropyl--D-thio-galactoside. Culture absorbance
at A600 was measured after overnight incubation at 37 °C.
X. laevis Oocytes Expression—Capped complementary RNA
(cRNA) was transcribed in vitro using theMessageMachine kit
(Ambion, Austin, TX). Oocyte isolationwas performed accord-
ing to established procedures (34, 35). Stage V-VI oocytes were
then selected and the following day injected with 50 nl of
diethylpyrocarbonate-treated water or cRNA solutions at 1
g/l using a semi-automatic injector (Drummond, Nanoject,
Broomall, PA).
Solute Uptake Assays in Oocytes—After 3–5 days from cRNA
injection, radiotracer uptake studies were carried out at 2 or 0.2
Ci/ml for 3H or 14C radiochemicals, respectively. At least 12
oocytes per group were incubated in 1 ml of Oocytes Ringer’s
solution, pH 7.4 (85 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 1 mM
Na2HPO4, 1mMCaCl2, 5mMHEPES) at room temperature and
then washed 12 times with Ringer’s solution at 4 °C. Individual
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oocytes were collected and immersed in 1 ml of scintillation
liquid. After overnight incubation, radioactivity was counted
on a Wallac 1450 Microbeta scintillation counter.
Indirect Immunofluorescence Assays—Human erythrocytes
infected with P. falciparum 3D7 were fixed with 10 pellet vol-
umes of 4% paraformaldehyde, 0.01% glutaraldehyde (30 min)
(36) and permeabilized with 10 pellet volumes of 0.1% Triton
X-100 in 4%BSA followed by a PBSwash. Polyclonal antibodies
from rabbit antisera were purified by proteinG affinity binding.
Antibodies against PfFT1 and PfFT2 were produced by immu-
nizing rabbits with keyhole limpet hemocyanin-conjugated
PfFT1 peptide QLIEKDINDDNHEN (amino acid residues
34–47) and PfFT2 peptide DPIVERTKSNGEGL (amino acid
residues 13–26). Both peptides and antibodies were produced
by GenScript. Anti-PfFT1 (0.811 mg/ml) and anti-PfFT2 (0.79
mg/ml) were used at 1:200 dilutions. The FITC-conjugated sec-
ondary antibody was purchased from Sigma (F0382) and used
at 1:1000 dilutions. Cells mounted with VectaShield Hard-
SetTM mounting medium (Vector Laboratories, Burlingame,
CA) were observed using a confocal microscope Zeiss Axiovert
200 M (L5M 5Pascal laser modules).
Green Fluorescent Protein (GFP) Recombinant Constructs
and Parasite Transfection—Recombinant PfFT1 and PfFT2
with GFP tags (cloned between AvrII and BsiWI sites in the
pLN-ENR-GFP plasmid) were generated to transfect P. falcip-
arum 3D7 as previously reported (37).
Data Analysis—Data are presented as the mean values and
their S.E. Statistical analyseswere performed as implemented in
GraphPad Prism 4 (GraphPad Software, La Jolla, CA) and
detailed in the tables and figures.
RESULTS
Putative Folate Transporter Genes in P. falciparum Encode
Transporters of the Major Facilitator Superfamily (MFS) and
the BT1 Family—MFS is the largest secondary transporter fam-
ily with a diverse substrate range of small hydrophilic solutes
that are transported in response to chemi-osmotic ion gradi-
ents (38). Two probable folate transporters were identified
from the P. falciparum genomic data base:MAL8P1.13 (PfFT1)
and PF11_0172 (PfFT2) (39). These are proteins of 505 and 455
amino acids, respectively, with 31% identity and 53% similarity
to each other andwith significant similarities (43.6% average) to
members of the high affinity BT1 folate transporters family,
part of the MFS (40) (TC 2.A.71 Transporter Classification
Database).
The topology and sequence signatures of MFS proteins (38,
40) are present in PfFT1 and PfFT2. Both P. falciparum pro-
teins contain a DX5GXRR sequence that is part of a larger MFS
signature in the loop L2–3 (40) and one of the two arginines
(PfFT1 R325; PfFT2 R311) usually present in the loop L8–9 of
MFS proteins (supplemental Figs. S1–S3). The arginines are
equivalent to the Leishmania FT1 R497, which has recently
been identified as a substrate binding residue (41). The
R113C/Smutation in L2–3 of the human proton-coupled folate
transporter hPCFT (42) has been demonstrated to be a loss-of-
functionmutation in patientswith hereditary folatemalabsorp-
tion (43, 44). Transmembrane segments (H1-H12) mainly
along H1 and H7 are much less conserved but known to con-
tribute to the substrate binding domains (45).
When PfFT1 and PfFT2 and functionally characterized
members of the BT1 family were aligned to the folate synthesis
enzyme dihydrofolate reductase (DHFR), remarkable similari-
ties were identified between the -helix segment B of P. fal-
ciparum DHFR that is known to interact with folates and anti-
folates (46) and residues of BT1 proteins preceding the
DX5GXRR motif described above (Fig. 1). In particular Asp-54
of P. falciparum DHFR, which is crucial for inhibitor (pyrim-
ethamine and WR99210 (Walter Reed Institute anti-DHFR
antifolate 99210)) and substrate binding, corresponds to the
well conserved first residue of DX5GXRR. Together with Asp-
54, other residues (Trp-48 and Phe-58) of the active site of
DHFR are also conserved in BT1 transporters (Fig. 1).
A third P. falciparum protein PF10_0215 has also been
reported as a potential folate transporter (39). However, we
observed no significant similarity between PF10_0215 and
either PfFT1 or PfFT2. When aligned against other MFS/BT1
proteins, the absence of the BT1 signatures in PF10_0215
becomes clear (Fig. 1 and supplemental Figs. S1 and S3).
PfFT1 and PfFT2 Localize to the P. falciparum Plasma
Membrane—We adopted two independent strategies for local-
ization studies, transfection with GFP-tagged gene constructs
and immunofluorescence. PfFT1 or PfFT2 were carboxyl-ter-
minal-tagged with GFP by cloning in the GFP plasmid pLN-
FIGURE 1. Folate binding region. Residues 45–66 of P. falciparumDHFR aligned to E. coliDHFR (residues 19–36) as in (46) are shown. Other sequences are as
in supplemental Figs. S1 and S3. Initial alignment was performed and prepared as in supplemental Fig. S3. Local alignment was optimizedmanually. Residues
that interact with folate substrates and antifolates aremarked at the top as Trp-48, Asp-54, and Phe-58 (46). Trp-48 is equivalent to theW100 in PfFT1, which is
absent in PfFT2.
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ENR-GFP (37) for subsequent transfection into P. falciparum
erythrocytic stages. PfFT1 localized to the parasite plasma
membrane of intraerythrocytic stages. In later trophozoite
stages, some intracellular vesicular structures appear to be
labeled (Fig. 2A). Transfection with the PfFT2-GFP fusion con-
struct was unsuccessful, and so this protein was localized by
indirect immunofluorescence. Subcellular localization of
PfFT2 resembles that of PfFT1, with prominent labeling of the
parasite plasma membrane and intracellular vesicles, with the
strongest signal observed in trophozoites and schizonts (Fig.
2B). Immunofluorescence with the anti-PfFT1 antibody
showed similar results (data not shown).
PfFT1 and PfFT2 Expressed in Xenopus Oocytes Transport
Folates and Folate Precursors—The X. laevis system has been
successfully employed in the functional characterization of a
number of mammalian folate transporters (47). As expected,
we observed endogenous folate uptake, although we measured
a greater level of folate uptake than was reported previously in
Xenopus oocytes (48). More importantly, both PfFT1 and
PfFT2 mediate the uptake of folates to levels significantly
greater than the water-injected controls. Preliminary experi-
ments using both fully oxidized and fully reduced folate sub-
strates showed that uptake is linear for at least 1 h (data not
shown). Later experiments were conducted over 40min, which
is within the linear phase of uptake.
Table 1 shows the uptake levels of folic acid by Xenopus
oocytes expressing PfFT1 or PfFT2 versus water-injected
controls. Both transporters are capable of transporting fully
oxidized FA to significantly greater levels than the water-
injected controls (p 0.001). Furthermore, transport of folic
acid was inhibited by an excess of unlabeled folic acid and by
the folate precursor pABA (p  0.01 and p  0.001, respec-
tively) (Table 1).
We have also investigated the transport of the fully reduced
folate derivative folinic acid. Aside from its possible presence
from clinical use, folinic acidwould not normally be available to
the parasite in vivo from host serum. However, folinic acid
shares structural similarities to 5-methyltetrahydrofolate and
offers the advantage of being considerablymore stable (13). Fig.
3 shows a comparison of folinic acid uptake byXenopus oocytes
expressing either PfFT1, PfFT2, or (as positive controls) the
human reduced folate carrier hRFC1 (49) or LtFT1 from Leish-
mania tarentolae (41). Oocytes expressing both the malarial
transporters and the positive controls take up significantly
more folinic acid than the water-injected controls (p 0.001).
In the case of PfFT1, PfFT2, and hRFC1, the differences are
about 5-fold and about 7-fold for LtFT1 (Fig. 3). In all cases
uptake of folinic acid is inhibited by 200 M PBN (an organic
anion transport inhibitor) andby 200Mmethotrexate, an anti-
folate transported by well characterized folate transporters
such as hRFC1 (49) and LtFT1 (41) (Fig. 4). Both PBN and
methotrexate have been shown to inhibit the uptake of folinic
acid into P. falciparum parasites (13, 16). PBN has been shown
to increase the sensitivity of parasites to antifolates both in vitro
and in vivo (16, 17).
We also looked at transport of the most abundant plasma
folate, 5-MTHF. Unexpectedly we found that uptake of
5-MTHF by oocytes expressing PfFT1 was not significantly dif-
ferent from the water control (data not shown). Significant
uptake of 5-MTHF was detected in oocytes expressing PfFT2
(Fig. 5). However, uptake of 5-MTHFby oocytes expressing this
transporter was a third less than that seen with the positive
control (hRFC1) and was much reduced compared with the
uptake of folinic acid (Figs. 3 and 4).
FIGURE 2.Cytolocalization of P. falciparum folate transporters PfFT1 and
PfFT2. A, fluorescence signals given by P. falciparum transformed with a
PfFT1-GFP C-terminal fusion construct are shown. A trophozoite (top panels)
shows a signal that coincides with the parasites plasmamembrane. Divid-
ing stages of early and late schizonts are in the two lower panels. In the
schizonts the labeling of merozoite plasma membranes is apparent.
B, indirect immunofluorescence of PfFT2 is shown. Permeabilized cells
were labeled with an anti-PfFT2 antibody as described under “Experimen-
tal Procedures.” Again trophozoites (upper and middle panels) as well as
merozoites in the schizont in the lower panel presented strong plasma
membrane signal. Bars represent 2 m.
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Malaria parasites are thought to be capable of synthesizing the
folate precursor pABA via the shikimate pathway (50). However,
there are numerous reports of antagonism of antifolate drugs by
external pABA, suggesting that pABAmight also be salvaged (5, 6,
12, 14, 51, 52). For this reason andgiven the results above (Table 1)
wewere interested to see ifpABAwas transported by thesemalar-
ial folate transporters. However, we found substantial uptake of
pABA into water-injected oocyte controls and obtained a poor
signal-to-noise ratio for measurement of uptake of radiolabeled
pABA after expressing PfFT1 or PfFT2 in Xenopus oocytes. The
presence of endogenous pABA transport in Xenopus oocytes and
thepotential for passive diffusionof substrate promptedus to seek
an alternative expression system.
Expression of PfFT1 and PfFT2 in E. coli Facilitates the Usage
of pABA—Folates cannot easily cross the inner membrane of
E. coli, an organism that relies on biosynthesis rather than sal-
vage of preformed folates (53). An E. colimutant with impaired
growth in the absence of exogenous pABA has been generated
by gene replacements of both the pABA synthesis enzymePabA
and the pABAG1 transporter AbgT (pabA/abgT), thus
impairing both the synthesis and the salvage of pABA (30, 31).
Folate transporters of the BT1 family have been successfully
characterized in this double mutant (30, 31, 54), and we have
made use of this approach for the bacterial expression of PfFT1
and PfFT2 constructs in the E. coli pabA/abgTmutant.
Fig. 6A shows the effect of increasing concentrations of exog-
enous FA on the growth of E. coli pabA/abgT expressing
either PfFT1 or PfFT2 compared with the plasmid-only control
pLOI707HE (abbreviated pLOI). The pLOI plasmid used as
control had the bla locus (ampicillin-resistant) removed from
the cloning site due to indications that it is detrimental andmay
cause a poor growth phenotype (30).
In each case growth of theE. coli knockouts expressing PfFT1
or PfFT2 was significantly increased relative to control across
the range of FA concentrations. In this system FA is an effective
TABLE 1
Uptake of folic acid by Xenopus oocytes expressing PfFT1 or PfFT2
Shown is [3H]folic acid uptake over 40min by oocytes injected with water or with cRNA for either of the PfFTs. Data are themeans and S.D. Experimental groups contained
27–48 oocytes per group. Data were obtained from at least three independent experiments (n 3). Statistical analysis was carried out withMann-WhitneyU tests between
groups of oocytes injected with PfFT1 or PfFT2 (rows) and between groups of oocytes incubated with different radiolabeled substrates (columns). NS (not significant)
denotes p 0.05.
Substrate
Uptake of folic acid
p valuesWater control PfFT1 PfFT2
pmol/oocyte/h
30 nM [3H]folic acid 1.070.27 2.920.48 3.450.71 0.001
30 nM [3H]folic acid 200 M folic acid 0.420.16 1.210.39 1.070.27 0.01
30 nM [3H]folic acid 200 M pABA 0.910.31 1.320.41 0.850.25 NS
p values NS 0.001 0.001
FIGURE 3. Uptake of [3H]folinic acid in Xenopus-expressing PfFT1 and
PfFT2. Oocytes injected with cRNA from PfFT1 and PfFT2 showed signifi-
cantly higher uptake of [3H]folinic acid in comparison to the water-injected
controls. Data are the mean and S.D. from at least 10 individual oocytes.
Uptake was assessed over 40 min. The folate transporters hRFC1 (44) and
LtFT1 (70) were used as positive controls. Although LtFT1 expression in Xeno-
pus oocytes has not been reported, it consistently presented the highest lev-
els of folate uptake. Significance values between groups of injected oocytes
was calculated with non-parametric Mann-Whitney U test using data for at
least three different experiments (n 3).
FIGURE 4. Inhibition of PfFT1 and PfFT2 dependent [3H]folinic acid
uptake inXenopusbymethotrexate and theorganic anion inhibitor pro-
benecid. Bothmethotrexate (MTX) and PBN at 200M significantly inhibited
folinic acid uptake (dark rectangles) via PfFT1 and PfFT2. Significance values
between groups of injected oocytes was calculated with non-parametric
Mann-Whitney U test using data for at least three different experiments
(n 3).
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rescue substrate in the low micromolar concentration range
(Fig. 6A). These results confirm the observations with Xenopus
oocytes that both PfFT1 and PfFT2 are capable of transporting
FA (Table 1). Fig. 6B shows the effect of exogenous pABA on
the growth of the same cell lines. Adding pABA to the medium
significantly increased growth in the cell lines, including the
control pLOI. Increased growth of the control could be due to a
low level pABA transport activity of the E. coli pabA/abgT
knock-out and/or a degree of passive diffusion of thisweak acid.
In any case, it is clear that growth is significantly increased
relative to the control in the lines expressing PfFT1 or PfFT2.
These results demonstrate that both PfFT1 andPfFT2 are capa-
ble of mediating the salvage of pABA, leading to growth rescue
in the bacterial expression system at low nanomolar external
concentrations.
Western blot analysis for PfFT2 to further corroborate its
expression in E. coli pabA/abgT was performed on mem-
brane-enriched fractions. However, these membrane prepara-
tions showed at best only very weak signals, and further immu-
noprecipitation using anti-PfFT2 was required. The
immunoprecipitate generated with anti-PfFT2 shows a band of
the expected size for PfFT2 (51.35 kDa) (supplemental Fig. S4)
that is absent in the E. coli pabA/abgT mutant expressing
the empty plasmid pLOI.
Fig. 6C summarizes the results of rescue experiments for a
variety of folates and related compounds illustrating twomajor
points; that is, the slower growth in the presence of polygluta-
mated forms (highly charged) of folate substrates or products
and the lack of rescue by the naturally circulating folate in
human plasma, 5-MTHF. Together with the dose-dependent
rescue at nanomolar levels by pABA shown in Fig. 6B, these
results confirm earlier observations with some cultured lines of
P. falciparum that pABA is an efficient salvage substrate at low
nanomolar external concentrations (11, 12). The monogluta-
mate derivative pABAG1 is also effective, although less efficient
than pABA itself. An additional glutamate, as in pABAG2 com-
pletely ablates the growth rescue seenwith pABAand pABAG1,
suggesting that further glutamation reduces transport effi-
ciency, as expected for a specific carrier-mediated membrane
transporter. Importantly, our results suggest that both PfFT1
and PfFT2 may play a greater role in the salvage of the folate
precursor pABA compared with preformed folates based on
available circulating concentrations of the substrates expected
in vivo.
Turning to the E. coli rescue with folate derivatives, the most
effective folate derivative is pteroic acid (corresponds to folic
acid without glutamate) both in its fully oxidized and dihydro
forms (Fig. 6C) followed by FA (carries one glutamate). Again,
the addition of more than one glutamate residue to the folate
molecule completely ablates the rescue (Fig. 6C).
Most surprisingly, 5-MTHF is a very poor substrate in this
system (Fig. 6C). As 5-MTHF is prone to oxidation, the levels of
5-MTHF in the bacterial culturemedia weremeasured bymass
spectroscopy at the end of the growth assays (24 h) and com-
paredwith the initial 5-MTHF levels when the cultures were set
up. After 24 h 90% of the initial 20 M 5-MTHF remained
intact (supplemental Fig. S5). Thus, at 18M this folate product
was present in comparable concentrations to the other folate
products tested. Thus, the modest effect by 5-MTHF in the
bacterial assays was not due to its extracellular oxidation. E. coli
is very capable of catalyzing the transfer of amethyl group from
methyltetrahydrofolate to homocysteine to formmethionine, a
reaction that regenerates the tetrahydrofolate cofactor (55).
The failure of external 5-MTHF to rescue these lines probably
reflects inefficient transport of this substrate by the malarial
transporters. These results mirror our findings with the trans-
porters expressed in Xenopus oocytes (Fig. 3) and seem to sug-
gest only a minimal role for the two transporters in the salvage
of this, themost abundant preformed folatemolecule in human
serum.
Antagonism of Antifolate Drug Action in Vitro—The effects
of adding micromolar concentrations of pABA, FA, FoA, or
5-MTHF on the antimalarial activity of antifolate drugs was
assessed for the dihydropteroate synthase inhibitors dapsone
and SDX and the DHFR inhibitors PYR and cycloguanil (sup-
plemental Table S1). Four differentP. falciparum isolates (HB3,
3D7, K1, and Dd2) with different dihydropteroate synthase and
DHFR genotypes and sensitivities to antifolates were used. The
growth inhibition assays were performed in media with low
folate prepared using folate-free RPMI and serum extensively
dialyzed to lower folate levels as has been common practice (5,
6, 14).
The antagonistic effects of pABA, FA, and FoA on the
antimalarial activity of the antifolates are presented in
FIGURE 5. Uptake of 5-[14C]methyltetrahydrofolate in Xenopus-express-
ing PfFT2. Oocytes injected with PfFT2 accumulated 5-[14C]MTHF at values
significantly above thewater-control. hRFC1 is known tohavehighaffinity for
reduced folates (Km 2–4M), and used as positive control here it validates the
expression system for uptake of this reduced folate. Data are the mean and
S.D. of groups with 24–36 oocytes. PBN used at 200M significantly reduced
5-[14C]MTHF uptake in both groups. Significance values between groups of
injected oocytes was calculated with non-parametric Mann-Whitney U test
using data for at least three different experiments (n 3).
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supplemental Table S1. The degree of antagonismwas depend-
ent on the parasite isolate, the particular antifolate drug, and
the specific folate supplement, as has been well documented
elsewhere (e.g. Refs. 4–6, 14, 15, and 56). However, two critical
observations substantiate the evidence compiled in the present
study. First, pABAprovides higher antagonism across the spec-
trum of antifolates and parasite strains studied. Second and in
contrast, 5-MTHF tends to be the poorest antagonist.
pABA and folate antagonism were next more accurately
assessed in P. falciparum 3D7 adapted to grow continuously in
pABA and folate freemedium. The concentrations of the folate
derivatives used this time were within the reported concentra-
tion range for human serum (57): 150 nM pABA, 25 nM
5-MTHF, and 0.5 nM FA. The levels of 5-MTHF in culture
media were confirmed by mass spectroscopy after 48 and 72 h,
at points when the parasite growth was assessed. Because
5-MTHF was reduced to88% of the initial levels by 48h (sup-
plemental Fig. S5), the initial concentrations were adjusted to
ensure thatwewould have 25 nM5-MTHFpresent by the end of
the parasite growth assays. Under these conditions the IC50
values for SDXandPYR in the absence of any folate supplemen-
tation were 26.15  12.13 nM and 0.5  0.05 pM, respectively.
These values are 4 and 5 orders of magnitude lower than the
sensitivity of the same parasites in the medium with low folate
(Table 2). At their physiological concentrations neither
5-MTHF nor FA had any detectable effects on the sensitivity of
the 3D7 strain to SDX or PYR (Tables 2 and 3). It is clear that
5-MTHF does not antagonize antifolates under physiological
conditions, a finding that is all the more surprising because
5-MTHF is the most prevalent preformed folate in human
serum (58). Crucially, these drug antagonism experiments
closely parallel the findings of the transport and rescue experi-
ments described above, which indicate that 5-MTHF is trans-
ported and salvaged only very poorly. This lack of antagonism
by 5-MTHFhas also been documented for theDHFR inhibitors
pyrimethamine and chlorcycloguanil (59).
In contrast, the addition of pABA at physiological levels
resulted in a significant antagonism of SDX (22-fold higher
IC50) and PYR (83-fold higher IC50) activities (p 0.001, Tables
2 and 3).We also found that the effect of pABAwas reduced by
PBN; IC50 values for SDX and PYR supplemented with pABA
were 4-fold and 2-fold lower, respectively, in the presence of
concentrations of PBN used in previous chemosensitization
studies (16) (Table 3). This is in agreement with the ability of
this anion transport inhibitor to inhibit PfFT1- and PfFT2-
driven folate uptake in oocytes. The data generated in these
studies are internally consistent with pABA being a substrate
with pharmacological impact at physiologically relevant con-
centrations for both transporters.
DISCUSSION
Malaria parasites are able to synthesize folate de novo, but
there is no doubt that they are also capable of taking up and
utilizing exogenous folate derivatives. Cultures ofP. falciparum
FIGURE 6. Bacterial expression of PfFT1 and PfFT2. A, shown is growth in
response to folic acid. Theeffect of folic acid (0–40M)on thegrowthof E. coli
pabA/abgT-carrying recombinant constructs of the tac promoter plasmid
pLOI707HE (32) with either PfFT1 or PfFT2 or the empty plasmid (pLOI was
used as the control) was determined. If we accept a maximum growth effect
at 40 M, the folic acid-effective concentrations (EC50) for PfFT1 and PfFT2
were calculatedas10.952.4 and102.0M, respectively. In theabsenceof
the transporter, pLOI, folic acid-induced growth stimulationwas significantly
lower and linear across the concentration range compared with the E. coli-
expressing PfFT1 and PfFT2. A600 on the y axis represents growth of the cul-
tures based on the absorbance of the broth measured at 600 nm as under
“Experimental Procedures.” Data taken from three different assays (n  3)
performed in triplicate. The differences in growth response to folic acid were
significant (p 0.001, two-way analysis of variancewith Bonferroni post test)
between bacteria carrying PfFT1 or PfFT2 and bacteria carrying the control
plasmid pLOI at all FA concentrations. B, shown is growth in response to
pABA. pABA (0–0.1 M) stimulated the growth of the E. coli mutants with
saturation occurring at around0.1M. Themaximumgrowth effect seenwith
pABA was achieved at 0.18 M, and the EC50 values were 3.7 0.4 and 3.1
0.6 nM for PfFT1 and PfFT2, respectively. In the case of the empty plasmid
(pLOI), the EC50was18 2.4 nM. Differences between bacteria carrying PfFT1
or PfFT2 and the control plasmid pLOI were significant (p 0.001, n 3, data
analysis as in A). C, growth response to folate precursors and derivatives is
shown. pABA glutamated with one or two residues (pABAG1; pABAG2) was
present at 20nM final concentration. Pteroic acid-equivalent to folic acidwith-
out a glutamate (Pte), dihydropteroic acid (DiPte), and diglutamated folic acid
(FA2) were present at 20M.Data are from triplicate observationswith at least
two experimental replicate assays (n 2). Statistical analysis was performed
with two-way analysis of variance and Bonferroni post-tests. The differences
in growth between bacteria carrying PfFT1 or PfFT2 and bacteria carrying the
control plasmid pLOI were significant for pABA, pABAG1, pteroic acid, dihy-
dropteroic acid, and folic acid (p 0.001) are denoted with an asterisk (*).
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can take up exogenous folic acid, folinic acid, and pABA and
convert it to polyglutamated folate end products (9, 12). Salvage
and catabolism of exogenous 5-MTHF (using a concentration
of 37 mM, 6 orders of magnitude higher than its physiological
levels) has also been shown with its methyl group being incor-
porated into methionine and the remaining co-factor joining
the folate pool in P. falciparum (7). Of the primary human
folate catabolites, pABAG1 was shown to be an alternative sub-
strate for malarial dihydropteroate synthetase, raising the pos-
sibility of salvage and direct utilization of pABAG1 in the para-
site folate pathway (60). One critically important aspect of
folate salvage is the mechanism by which folate derivatives are
taken into the intracellular parasite. Exogenous folates and pre-
cursors must pass through the host erythrocyte membrane, the
parasitophorous vacuole membrane, and the parasite plasma
membrane en route to the parasite cytoplasm. The findings of a
recent study suggest that it is unlikely that either the host eryth-
rocyte membrane or the parasitophorous vacuole membrane
provides a rate-limiting barrier to folate salvage in P. falcipa-
rum (13). In this study it was also shown that the uptake of
folates across the parasite plasmamembranewas regulated, sat-
urable, inhibitable, and energy-dependent, thus exhibiting the
properties of a carrier-mediated membrane transport process
(13).
Here we have identified PfFT1 and PfFT2 and generated data
to support their role as P. falciparum folate transporters. The
predicted proteins display significant similarities to members
of the high affinity BT1 folate transporter group (TC 2.A.71).
Both PfFT1 and PfFT2 appear to be localized predominantly to
the plasma membrane in intraerythrocytic P. falciparum (Fig.
2). Both the identified malarial transporters exhibit broad sub-
strate specificity capable of transporting FA, FoA, 5-MTHF,
pteroic acid, dihydropteroic acid, pABA, and pABAG1 (Table 1,
Figs. 3–6). In this respect they are similar to plant members of
the BT1 family that are assumed to be able to transport mono-
glutamyl forms of any naturally occurring folate (31). Here,
both PfFT1 and PfFT2 are also capable of transporting the
human folate catabolite pABAG1 (Fig. 6C), whereas other BT1
familymembers apparently do not transport this substrate (31).
As pABAG1 is a product of folate catabolism in humans (61),
circulating in plasma at estimated concentrations of 160 nM
(62), the results presented here open the possibility of malaria
parasites also being able to salvage products of host folate
catabolism.
Our results indicate that pABA and pABAG1 are better sal-
vage substrates compared with preformed folates. These find-
ings are in agreement with an earlier study using intact parasite
cultures showing that pABA was more efficiently taken up and
converted to polyglutamated end products than were pre-
formed folates (12). Furthermore, the conclusion that 5-MTHF
is a poor salvage substrate is consistent with the very weak
antagonism of antifolate antimalarial activities cause by
5-MTHF reported elsewhere (59).
Although P. falciparum has been shown to require aminimal
amount of folate to survive long term in in vitro culture in the
absence of pABA (i.e. 226.5 nM FA (51)), we have successfully
cultured P. falciparum 3D7 continuously in the absence of
pABA or folates. This allowed us to investigate the effects
of very low concentrations of folates and pABA, representative
of those encountered in the plasma of the human host. Under
these physiologically relevant conditions only pABAcaused any
significant antagonism of antifolate activity (Tables 2 and 3).
TABLE 2
Effect of exogenous folate supplementation on the in vitro inhibitory activity of antifolates against P. falciparum 3D7 adapted to continuous
culture in folate and pABA free media
IC50 values obtained from 3D7 parasites were cultured in either dialyzed media (folate-free RPMI-1640 and dialyzed serum) or “free” media (folate- and pABA-free
RPMI-1640 and Albumax II). Folate supplements were present at the following concentrations: for dialyzed media, 7.3M pABA and 2.3 M for both 5-MTHF and FA; for
free media, 150 nM pABA, 25 nM 5-MTHF, and 0.5 nM FA. Values represent the mean S.D. and n 4–7. In all comparisons between free and dialyzed media there was
a statistical difference (p 0.0001, t test), with the values observed with dialyzed media always higher than the folate-free media. pABA significantly antagonized antifolate
activity under both sets of culture conditions for both SDX and PYR (p 0.05), whereas 5-MTHF had no effect, and FA was only significant with SDX in dialyzed media
(p 0.05).
Supplements
IC50 values
SDX PYR
Dialyzed Free Dialyzed Free
M nM nM pM
Control 426.1385.46 26.1512.13 50.1011 0.50.05
pABA 1952.33189.98 572.43145.36 90.212 41.863.11
5-MTHF 472.2542.11 23.2815.29 70.309 0.390.06
FA 1572.06413.66 33.1522.23 100.430 0.360.06
TABLE 3
The impact of probenecid on pABA or folate-induced antagonism of antifolate activity in P. falciparum in vitro
Values are shown for assays carried out in folate and pABA-free RPMI-1640media containing Albumax II. Supplements were present at 150 nM pABA, 25 nM 5-MTHF, and
0.5 nM FA. PBNwas present at 150 M. Values are presented as the mean S.D. n 5–6. Probenecid significantly reduced the impact of supplementation on antimalarial
drug activity (p 0.01).
Supplements
IC50 values
SDX SDX PBN PYR PYR PBN
nM pM
Control 27.312.13 1.30.61 0.50.05 0.30.02
pABA 545145 14134 41.73.11 27.62.55
5-MTHF 22.315.29 1.10.42 0.40.06 0.240.10
FA 31.722.23 1.50.35 0.350.06 0.220.03
pABA 5-MTHF FA 594102 15022 44.93.11 26.451.32
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It has proven technically difficult to demonstrate direct
transport of pABA by PfFT1 and PfFT2. This difficulty has also
been encountered with folate transport assays mediated via
other BT1 transporters. TheXenopus oocyte systemdisplayed a
high background of pABA uptake at neutral pH (10 pmol/
oocyte/h) that we have been unable to reduce.Wemoved to the
bacterial system to overcome some of the limitations of the
Xenopus model. However, as a vitamin, only very low levels of
protein expression and low levels of substrate transport (in our
case pABA and folates) are required to salvage the E. coli
mutants. The concentrations involved are below the sensitivity
of the analytical methods available. Other groups have explic-
itly reported their inability to express BT1 homologs (e.g. Syn-
echocystis andArabidopsis BT1 family of folate transporters) to
levels suitable for kinetic studies despite considerable effort
(30). In the absence of a direct method to measure folate trans-
port activity within an acceptable time scale, we believe that
E. coli rescue, as used here, is themost sensitive indirect system
available by which PfFT1- and PfFT2-mediated pABA and
folate salvage can be characterized.
In assessing the functional significance of our observations it
seems relevant to consider the physiological levels of folate
derivatives as they occur in humanblood and plasma. The latest
available data from the National Health and Nutrition Exami-
nation Surveys in the United States puts the median red cell
folate levels of the United States population (4 years of age and
older) at 266 ng/ml, whereas the median serum folate levels are
12.2 ng/ml or about 27 nM (57). A recent liquid chromatogra-
phy-tandem mass spectrometry analysis of folate and folate
catabolites in human serum shows that in normal individuals
about 98% of serum folate is in the form of 5-MTHF (or its
primary oxidized derivative 4--hydroxy-5-methyltetrahydro-
folate monoglutamate), and about 2% is in the form of FA (58).
Thus, physiological concentrations of 5-MTHF and FA in
human serum are 26.5 nM and 540 pM, respectively. When
these concentrations of folateswere added to folate-free culture
media, we found no significant antagonism of antifolate drugs
in cultures of P. falciparum 3D7 (Tables 2 and 3).
The physiological concentration of pABA in human serum is
known to be highly variable. In a study of 90 serum samples
from blood donors, approximately half of the cohort had serum
pABA concentrations between 145 nM and 6.1 M (63). If these
figures reflect serum pABA concentrations in the general pop-
ulation, then our results and those of others suggest that the
concentrations of serum pABAmay be high enough to antago-
nize antifolate activity in a significant number of patients (4, 6).
Malaria parasites are capable of synthesizing pABA de novo
via the shikimate pathway (10, 50). However, pABA synthesis
does not seem to be sufficient for parasite survival in vivo; over
many years, studies performed in rodents, monkeys, and
humans have all shown that a pABA-deficient diet may help to
protect the host from a variety of malaria species (8, 64–69). In
this respect pABA salvage seems more important than the sal-
vage of preformed folates. Because pABA is neither required
nor synthesized by the human host, its salvage is potentially an
attractive target for chemotherapy. For instance, the use of
pABA-deficient diets or the use of inhibitors to block pABA
salvage at the level of PfFT1 or PfFT2may improve the antima-
larial efficacy of several classes of antimalarial drugs including
the antifolates and inhibitors of the shikimate pathway (3, 8).
In summary we report the identification and characteriza-
tion of two transporters, PfFT1 and PfFT2, that mediate the
salvage of folate derivatives and precursors in P. falciparum.
We propose a new vision of folate salvage by the intraerythro-
cytic malaria parasite; folate salvage occurs via the import of
pABA rather than preformed folates. This could explain why
dihydropteroate synthase inhibitors retain their efficacy and
synergy with DHFR inhibitors in the presence of physiological
folate concentrations as well as presenting potential new
opportunities for the development of antimalarial therapies.
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